Allodynia, meaning "other pain", is a painful (noxious) response to a usually non-painful (innocuous) stimulus and can be either static or mechanical. Allodynia differs from referred pain, but can occur in areas other than the one stimulated. It is dysesthetic. Allodynia is different from hyperalgesia, an extreme reaction to a stimulus which is normally painful.
Using PET scans of the brain, University of Michigan researchers showed that dopamine falls and fluctuates at different times during a migraine headache.
Drinking highly caffeinated alcoholic beverages triggers changes in the adolescent brain similar to taking cocaine, and the consequences last into adulthood as an altered ability to deal with rewarding substances, according to a Purdue University study.
Botulinum toxin A injections have a sustained beneficial effect in patients with neuropathic pain, shows a randomised trial.
Chronic pain affects hundreds of millions of people worldwide and is a major cause of disability, causing more disability than cancer and heart disease. Canadian researchers, including Michael Salter at SickKids are shedding light on the molecular dynamics of chronic pain. They have uncovered a critical role for a class of cells present in the brain and spinal cord, called microglia, in pain.
Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.
Some people experience cold not only as feeling cold, but actually as a painful sensation. This applies even to fairly mild temperatures - anything below 20°C.
Peripheral or central nerve injury often leads to neuropathic pain, a chronic condition that can manifest behaviorally as spontaneous pain, hyperalgesia and allodynia, and which also results in neurological dysfunction.
For the 8th time the European Federation of IASP Chapters in cooperation with the pharmaceutical company Grünenthal Group announced the EFIC-Grünenthal-Grant (E-G-G) - a grant aimed to support young scientists at an early stage of their experimental projects on clinical and human volunteer-based pain research.
Nearly 1 in 10 stroke patients suffer chronic and debilitating pain, typically described as sharp, stabbing or burning. It's called central poststroke pain syndrome (CPSP). It was first described more than 100 years ago, and it is treatable with medications and magnetic or electrical stimulation of the brain.
Researchers at Rush University Medical Center, in collaboration with researchers at Northwestern University, have identified a molecular mechanism central to the development of osteoarthritis (OA) pain, a finding that could have major implications for future treatment of this often-debilitating condition.
Companionship has the potential to reduce pain linked to nerve damage, according to a new study.
Chronic nerve pain results from pathological changes within a nerve that appear to be self-sustaining and thus the pain continues for a long time.
MAP Pharmaceuticals, Inc. today announced that the Company will present data on LEVADEX (formerly MAP0004), an orally inhaled investigational drug for the acute treatment of migraine, at the 54th Annual Scientific Meeting of the American Headache Society (AHS) in Los Angeles, CA, June 21-24, 2012.
Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.
A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.
Cannabidiol—a compound derived from marijuana—may be a promising new treatment to prevent the development of painful neuropathy in patients receiving the chemotherapy drug paclitaxel, according to animal experiments reported in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
Michael L. Oshinsky, Ph.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and a member of the Jefferson Headache Center team, was recently named the 2011 Harold G. Wolff Lecture award recipient for creating a new animal model of migraine headache.
The diabetes drug rosiglitazone (Avandia) can control inflammation leading to nerve damage and abnormal pain responses, suggests a paper in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.
DARA BioSciences, Inc. announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier.